日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Clonal Evolution and Lineage Switch from T-Cell Acute Lymphoblastic Leukemia to Acute Myeloid Leukemia in Therapy-Resistant PICALM::MLLT10 Leukemia

治疗耐药性 PICALM::MLLT10 白血病中从 T 细胞急性淋巴细胞白血病到急性髓系白血病的克隆演化和谱系转换

Kawamura, Machiko; Sadato, Daichi; Haruta, Masayuki; Kubota, Nobuko; Harada, Yuka; Kobayashi, Takeshi; Doki, Noriko; Kasai, Fumio; Nishimura, Yu; Kobayashi, Hirofumi; Maseki, Nobuo

A therapeutic effect of Forodesine for CNS relapsed primary testicular T cell lymphoma after allogeneic transplantation

福地辛对同种异体移植后中枢神经系统复发的原发性睾丸T细胞淋巴瘤的治疗效果

Tsutsumi, Hiroki; Kudo, Masahisa; Maseki, Nobuo; Sekiguchi, Yasunobu; Kobayashi, Hirofumi

Successful Treatment of Leukemic Synovitis Complicated With Chronic Myelomonocytic Leukemia

成功治疗合并慢性粒单核细胞白血病的白血病性滑膜炎

Tsutsumi, Hiroki; Kudo, Masahisa; Maseki, Nobuo; Kawamura, Machiko; Kobayashi, Kazuhiko; Sekiguchi, Yasunobu; Harada, Yuka; Sadato, Daichi; Kobayashi, Hirofumi

Treatment with epcoritamab in 10 patients in real-world clinical practice

在真实世界临床实践中,10 例患者接受了 epcoritamab 治疗

Sekiguchi, Yasunobu; Tsutsumi, Hiroki; Kudo, Masahisa; Maseki, Nobuo; Iizaki, Yoshie; Kawamura, Machiko; Kobayashi, Kazuhiko; Nishimura, Yu; Kanda, Hiroaki; Takei, Daisuke; Abe, Tomoya; Hanai, Makoto; Nakayama, Toshiaki; Shimano, Yasumasa; Kobayashi, Hirofumi

Fludarabine plus reduced-intensity busulfan versus fludarabine plus myeloablative busulfan in patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic cell transplantation

氟达拉滨联合减低强度白消安与氟达拉滨联合清髓性白消安治疗接受异基因造血干细胞移植的非霍奇金淋巴瘤患者的疗效比较

Kamijo, Kimimori; Shimomura, Yoshimitsu; Shinohara, Akihito; Mizuno, Shohei; Kanaya, Minoru; Usui, Yoshiaki; Kim, Sung-Won; Ara, Takahide; Mizuno, Ishikazu; Kuriyama, Takuro; Nakazawa, Hideyuki; Matsuoka, Ken-Ichi; Kusumoto, Shigeru; Maseki, Nobuo; Yamaguchi, Masaki; Ashida, Takashi; Onizuka, Makoto; Fukuda, Takahiro; Atsuta, Yoshiko; Kondo, Eisei

Use of R-mini-CHP in combination with polatuzumab vedotin (pola-R-mini-CHP) as the primary treatment in ≥80-year-old cases with diffuse large B-cell lymphoma

在≥80岁的弥漫性大B细胞淋巴瘤患者中,使用R-mini-CHP联合polatuzumab vedotin(pola-R-mini-CHP)作为一线治疗

Sekiguchi, Yasunobu; Tsutsumi, Hiroki; Gomyo, Ayumi; Kudo, Masahisa; Iizaki, Yoshie; Maseki, Nobuo; Kawamura, Machiko; Kobayashi, Kazuhiko; Nishimura, Yu; Kanda, Hiroaki; Nitta, Hideaki; Noguchi, Masaaki; Kobayashi, Hirofumi

Gilteritinib Monotherapy as a Transplant Bridging Option for a Patient with FLT3-Mutated Acute Promyelocytic Leukemia Who Developed a Second Relapse after All-Trans Retinoic Acid + Chemotherapy, Arsenic Trioxide, and High-Dose Cytarabine Therapy

吉瑞替尼单药治疗作为移植桥接方案,用于治疗一名在接受全反式维甲酸联合化疗、三氧化二砷和高剂量阿糖胞苷治疗后出现第二次复发的FLT3突变急性早幼粒细胞白血病患者。

Kobayashi, Hirofumi; Tsutsumi, Hiroki; Misaki, Yukiko; Maekawa, Takashi; Inoshita, Naoko; Kawamura, Machiko; Maseki, Nobuo

Radiotherapy for localized gastric mucosa-associated lymphoid tissue lymphoma: long-term outcomes over 10 years

局部胃黏膜相关淋巴组织淋巴瘤的放射治疗:10 年以上的长期疗效

Ohkubo, Yu; Saito, Yoshihiro; Ushijima, Hiroki; Onishi, Masahiro; Kazumoto, Tomoko; Saitoh, Jun-Ichi; Kubota, Nobuko; Kobayashi, Hirofumi; Maseki, Nobuo; Nishimura, Yu; Kurosumi, Masafumi

Extracellular NM23 protein promotes the growth and survival of primary cultured human acute myelogenous leukemia cells.

细胞外NM23蛋白促进原代培养的人类急性髓系白血病细胞的生长和存活

Okabe-Kado Junko, Kasukabe Takashi, Honma Yoshio, Kobayashi Hirofumi, Maseki Nobuo, Kaneko Yasuhiko